Kieburtz K D, Seidlin M, Lambert J S, Dolin R, Reichman R, Valentine F
Department of Neurology, University of Rochester School of Medicine, New York.
J Acquir Immune Defic Syndr (1988). 1992;5(1):60-4.
Neuropathic complaints were frequently observed in a Phase I study of dideoxyinosine (ddI) in 44 patients with AIDS and AIDS-related complex. Ten patients (23%) were thought to have a ddI-related peripheral neuropathy. The symptoms were primarily sensory, and there was limited motor involvement. The sensory symptoms improved in all patients with discontinuation of ddI. Some patients tolerated reintroduction of ddI at lower doses without significant recurrence of the neuropathic symptoms. Although the neuropathy was usually seen in patients taking higher doses of ddI than used in current treatment protocols, clinicians must be aware of this potential toxicity as more human immunodeficiency virus-infected patients are being treated with ddI.
在一项对44例艾滋病及艾滋病相关综合征患者进行的双脱氧肌苷（ddI）I期研究中，经常观察到神经病变主诉。10例患者（23%）被认为患有与ddI相关的周围神经病变。症状主要为感觉性，运动受累有限。所有停用ddI的患者感觉症状均有改善。一些患者能耐受较低剂量重新使用ddI，且神经病变症状无明显复发。尽管神经病变通常见于服用高于当前治疗方案剂量ddI的患者，但随着越来越多的人类免疫缺陷病毒感染患者接受ddI治疗，临床医生必须意识到这种潜在毒性。
